Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Rigel plans to focus on completing three clinical programs for ITP, DLE and dry eye disease

Rigel Pharmaceuticals, Inc. today announced its plans to focus the Company's resources on the completion of three lead clinical programs. These efforts include commencing a Phase 3 clinical study of fostamatinib, an oral SYK inhibitor, in Immune Thrombocytopenic Purpura pending discussions with regulatory agencies.

5 Sep 2013

Research into 'personalised' medicine is being led by Greenwich team

Research into 'personalised' medicine is being led by a University of Greenwich team. Currently, many medicines which are prescribed to patients either do not work properly or have some significant side effects. The aim of personalised medicine, sometimes called 'precision' medicine, is to ensure that the most appropriate medicine is given to each patient and that the medicine is both effective and safe.

5 Sep 2013

£13M partnership to accelerate cancer-focused drug discovery launched by Queen's and Almac Discovery

A new -13 million partnership to accelerate cancer-focused drug discovery in Northern Ireland has been launched by Enterprise Minister Arlene Foster MLA.

5 Sep 2013

Repligen Earns $1M Pfizer Milestone Payment

...

4 Sep 2013

Apitope successfully completes ATX-MS-1467 Phase I trial in relapsing MS patients with positive results

Apitope, the drug discovery and development company focused on treating the underlying cause of autoimmune diseases, today announced completion with positive results of its second Phase I clinical trial of ATX-MS-1467.

3 Sep 2013

University of Warwick professor wins Discovery STAR Award to identify new treatment for Chagas disease

Domainex Ltd., a drug discovery company specialising in translational research support, has announced that the recipient of its first Discovery STAR Award; Professor Vilmos Fulop of the University of Warwick.

3 Sep 2013

Researchers identify origin of human TB

Tuberculosis remains one of deadliest infectious diseases of humans, killing 50% of individuals when left untreated. Even today, TB causes 1-2 million deaths every year mainly in developing countries. Multidrug-resistance is a growing threat in the fight against the disease.

2 Sep 2013

New angle for developing drugs to prevent thrombosis and heart attack

Platelets, which allow blood to clot, are at the heart of numerous cardiovascular problems, including heart attacks and stroke. New research has uncovered a key platelet protein that could offer a new angle for developing drugs to prevent thrombosis, or dangerous blood clots, in patients who are at high risk such as those with atherosclerosis or a history of heart problems.

31 Aug 2013

Future of biomedical innovation depends on new trend for all players to work together for common goal

It's a long, expensive, risky road to turn a scientific breakthrough into a treatment that can help patients. Fewer organizations are trying to tackle the challenges alone, says a new paper from MIT researchers published August 28 in the journal Science Translational Medicine.

29 Aug 2013

Haplogen, Cemm Offer Huge Collection Of Mutant Cell Lines

...

27 Aug 2013

Haplogen, Cemm Offer Huge Collection Of Mutant Cell Lines

...

27 Aug 2013

2ml deep well plate launched by Porvair Sciences

Porvair Sciences has developed the first 96-well round deep well plate that genuinely delivers 2.00 ml liquid capacity / well in an automation compatible SLAS / ANSI footprint. The revolutionary "common wall" design provides a full 2ml round well, round bottom well within a 45mm height limit, thus ensuring full compatibility with most plate handling equipment.

From Porvair Sciences Limited 27 Aug 2013

Research finding could lead to potential treatment for lymphedema

The molecule interleukin-7 is an important immune messenger protein which ensures that a sufficient number of T cells are present in our body for immune defence. Researchers from ETH Zurich have now demonstrated that IL-7 has another important function: it enhances the drainage function of lymphatic vessels, which collect fluid that has leaked out of blood vessels into the body tissue and return it to the bloodstream.

27 Aug 2013

Unique computer technology opens up discovery of smarter drugs to treat illnesses

A unique computer technology that opens up the discovery of smarter drugs to treat major illnesses including heart disease has been invented by University of Strathclyde scientists.

27 Aug 2013

UAB study points to protein pathway that could lead to new treatments for diabetes

The same protein tells beta cells in the pancreas to stop making insulin and then to self-destruct as diabetes worsens, according to a University of Alabama at Birmingham study published online today in the journal Nature Medicine.

27 Aug 2013

Shire Renews Rare Genetic Disease Collab With Santaris

...

23 Aug 2013

Shire Renews Rare Genetic Disease Collab With Santaris

...

23 Aug 2013

INTEGRA Biosciences enters into UK market with local sales team

INTEGRA Biosciences has announced, as of August 1st 2013, a direct sales / support team in the UK to further improve support of its local customer base.

From INTEGRA Biosciences 23 Aug 2013

Shire extends existing partnership with Santaris Pharma in rare genetic disease space

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that its long term partner, Shire has extended the existing partnership in the rare genetic disease space.

23 Aug 2013

Psychogenics Picks Up Alzheimer’s Animal Model From USF

PsychoGenics obtained an exclusive license from the University of South Florida to its APP/PS1 double transgenic mice, which co-express the M146L presenilin 1 (PS1) mutation and the double mutations at K670N/M671L (Swedish mutation) in the amyloid precursor protein (APP).

22 Aug 2013

Drug Discovery News and Research

Further Reading

Rigel plans to focus on completing three clinical programs for ITP, DLE and dry eye disease

Research into 'personalised' medicine is being led by Greenwich team

£13M partnership to accelerate cancer-focused drug discovery launched by Queen's and Almac Discovery

Repligen Earns $1M Pfizer Milestone Payment

Apitope successfully completes ATX-MS-1467 Phase I trial in relapsing MS patients with positive results

University of Warwick professor wins Discovery STAR Award to identify new treatment for Chagas disease

Researchers identify origin of human TB

New angle for developing drugs to prevent thrombosis and heart attack

Future of biomedical innovation depends on new trend for all players to work together for common goal

Haplogen, Cemm Offer Huge Collection Of Mutant Cell Lines

Haplogen, Cemm Offer Huge Collection Of Mutant Cell Lines

2ml deep well plate launched by Porvair Sciences

Research finding could lead to potential treatment for lymphedema

Unique computer technology opens up discovery of smarter drugs to treat illnesses

UAB study points to protein pathway that could lead to new treatments for diabetes

Shire Renews Rare Genetic Disease Collab With Santaris

Shire Renews Rare Genetic Disease Collab With Santaris

INTEGRA Biosciences enters into UK market with local sales team

Shire extends existing partnership with Santaris Pharma in rare genetic disease space

Psychogenics Picks Up Alzheimer’s Animal Model From USF

Drug Discovery - Second Edition eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest Life Science News